School of Chemical and Physical Sciences, Victoria University of Wellington, PO Box 600, Wellington, New Zealand; Centre for Biodiscovery, Victoria University of Wellington, PO Box 600, Wellington, New Zealand.
Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, B.C, Canada.
Carbohydr Res. 2024 Sep;543:109198. doi: 10.1016/j.carres.2024.109198. Epub 2024 Jun 27.
Trihydroxypiperidines are a therapeutically valuable class of iminosugar. We applied a one-pot amination-cyclisation cascade reaction to synthesise 3,4,5-trihydroxypiperidine stereoisomers in three steps from commercially available pentoses and in excellent overall yields. Using our methodology, the yields of the syntheses of meso-1, meso-2 and 3L are the highest reported to date. The synthetic methodology was readily extended to the three-step synthesis of N-alkyl derivatives by replacing the ammonia nitrogen source with a primary amine. The trihydroxypiperidines and N-alkyl analogues were screened for enzyme inhibitory activity using Fabrazyme (Fabry disease), GCase (Gaucher's disease), Agrobacterium sp. β-glucosidase, and Escherichia coli β-galactosidase. N-Phenylethyl 3,4,5-trihydroxypiperidine (N-phenylethyl-1-(3R,4R,5S)-piperidine-3,4,5-triol) showed good inhibitory activity of Fabrazyme (K = 46 μM). This activity was abolished when the N-phenylethyl group was removed or replaced with a non-aromatic alkyl chain.
三羟基哌啶是一类具有治疗价值的亚氨基糖。我们应用一锅胺化-环化级联反应,从商业可得的戊糖出发,经三步反应以优异的总收率合成了 3,4,5-三羟基哌啶立体异构体。采用我们的方法,meso-1、meso-2 和 3L 的合成产率是迄今为止报道的最高产率。通过用伯胺替代氨氮源,该合成方法很容易扩展到 N-烷基衍生物的三步合成。用 Fabrazyme(法布里病)、GCase(戈谢病)、农杆菌β-葡萄糖苷酶和大肠杆菌β-半乳糖苷酶对三羟基哌啶和 N-烷基类似物进行了酶抑制活性筛选。N-苯乙基 3,4,5-三羟基哌啶(N-苯乙基-1-(3R,4R,5S)-哌啶-3,4,5-三醇)对 Fabrazyme 表现出良好的抑制活性(K=46μM)。当 N-苯乙基被去除或被非芳族烷基链取代时,这种活性就会消失。